In the wake of this month’s Vioxx headlines comes this story:
Just days before a medical journal was to publish a Food and Drug Administration-sponsored study that raised concerns about the safety of the arthritis drug Vioxx, an FDA official took the unusual step of calling the editor to raise questions about the findings’ scientific integrity.
Recent Comments